L606 (liposomal treprostinil) injection

About Liquidia

Liquidia's mission is to develop best-in-class therapies for rare cardiopulmonary diseases, helping patients breathe easier and live longer. The company has successfully transitioned from a technology platform to a commercial entity with the FDA approval and launch of YUTREPIA™ for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its strategy centers on maximizing the commercial potential of YUTREPIA™, advancing its pipeline through clinical development, and exploiting the versatility of its PRINT® platform for future inhaled therapeutics.

About Liquidia Corporation

Liquidia Corporation is a clinical-stage biopharma focused on developing and commercializing therapies for pulmonary hypertension and related diseases using its proprietary PRINT® particle engineering platform. Its key achievement is the FDA approval of YUTREPIA™ (treprostinil) inhalation powder for PAH, positioning the company for a transition to a commercial entity. The strategy centers on successfully launching YUTREPIA™, expanding its label into additional pulmonary hypertension indications, and advancing its pipeline of PRINT®-enabled formulations. The company's value is rooted in its unique manufacturing technology, which creates differentiated, patient-friendly drug products.

Therapeutic Areas

Other Pulmonary Arterial Hypertension (PAH) Drugs